AVITA Medical, Inc. RCEL revenue by segment, product and geography
In its fiscal year ending 2025-12-31, AVITA Medical, Inc. reported revenue across 2 products and services; the largest, Recell Go Preparation Kit, was $35.8M, 85.6% of the filed sum (+104.6% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Recell Go Preparation Kit$35.8M85.6%+104.6% yoy
- Permeaderm$6M14.4%no prior
Members sum to $41.8M against $70.9M consolidated (residual $29.1M) - eliminations or corporate lines the filer did not tag on this axis.
- United States$68.8M96.1%+10.7% yoy
- Japan$2.09M2.9%+45.9% yoy
- United Kingdom$486K0.7%+148.0% yoy
- Australia$200K0.3%-35.9% yoy
- European Union$49K0.1%-68.4% yoy
Members sum to the consolidated $70.9M for this period.
- Recell Go Preparation Kit$9.4M100.0%-1.1% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.